Table 3.
Multilevel linear regression (biomarkers to changes in LV Ejection Fraction from V1 to V6)
| Coef. | SE | DF | t | p | |
|---|---|---|---|---|---|
| εcc (%) | −1.5540 | 0.3924 | 35 | −3.9605 | <.001 |
| ESV (ml) | −0.2496 | 0.0446 | 43 | −5.5980 | <.001 |
| ESFS (g/cm2) | −0.1584 | 0.0451 | 43 | −3.5114 | .0011 |
| MMP7 (pg/ml) | −0.0014 | 0.0006 | 43 | −2.4592 | .018 |
| sIL 4R (pg/ml) | 0.0034 | 0.0014 | 44 | 2.4405 | .0188 |
| sRage (pg/ml) | −0.0502 | 0.0216 | 44 | −2.3234 | .0248 |
| sTNFRI (pg/ml) | −0.0032 | 0.0015 | 44 | −2.1340 | .0385 |
| sTNFRII (pg/ml) | −0.0008 | 0.0003 | 44 | −2.4872 | .0167 |
| sVEGFR3 (pg/ml) | −0.0058 | 0.0022 | 44 | −2.6162 | .0121 |
V1: first visit; V6: 1 year after maximal anthracycline therapy; εcc: Peak global longitudinal strain magnitude; ESV: End systolic volume; ESFS: End systolic fiber stress; MMP: Metalloproteinase; sILR: soluble interleukin receptor; sRage: receptor for advanced glycation end products; sTNFR: soluble receptor for TNF; sVEGFR: receptors for vascular endothelial growth factor